A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure

Diabetic Medicine

Volumn 31, Issue 9, 2014, Pages 1032-1038

  Adam, W R ^a   O'Brien, R C ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LACTIC ACID; METFORMIN; PHENFORMIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

BLOOD PH; CHRONIC KIDNEY FAILURE; DIABETIC PATIENT; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG OVERDOSE; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA; PRACTICE GUIDELINE; RENAL REPLACEMENT THERAPY; REVIEW; ACIDOSIS, LACTIC; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS; DRUG ADMINISTRATION; DRUG EFFECTS; PATHOPHYSIOLOGY; PH; TREATMENT OUTCOME;

ACIDOSIS, LACTIC; DIABETES MELLITUS; DRUG ADMINISTRATION SCHEDULE; DRUG OVERDOSE; GLOMERULAR FILTRATION RATE; GUIDELINE ADHERENCE; HUMANS; HYDROGEN-ION CONCENTRATION; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; LACTIC ACID; METFORMIN; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84906093541     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12515     Document Type: Review

References (43)

1. Kajbaf F, Arnouts P, de Broe M, Lalau JD. Metformin therapy and kidney disease: a review of guidelines and proposals for metformin withdrawal around the world. Pharmacoepidemiol Drug Saf 2013; 10: 1027-1035.
2. Heaf JG. Biesen Wv. Metformin and chronic renal impairment: a story of choices and ugly ducklings. Clin Diabetes 2011; 20: 97.
3. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011; 34: 1431-1437.
4. Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract 2011; 118: c380-383.
5. Holman RR. Type 2 diabetes mellitus in 2012: optimal management of T2DM remains elusive. Nat Rev Endocrinol 2013; 9: 67-68.
6. Cicero AF, Tartagni E, Ertek S. Metformin and its clinical use: new insights for an old drug in clinical practice. Arch Med Sci 2012; 8: 907-917.
7. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
8. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
9. Ekstrom N, Schioler L, Svensson AM, Eeg-Olofsson K, Miao Jonasson J, Zethelius B et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. Br Med J Open 2012; 2: e001076.
10. Solini A, Penno G, Bonora E, Fondelli C, Orsi E, Trevisan R et al. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the renal insufficiency and cardiovascular events italian multicenter study. J Am Geriatr Soc 2013; 61: 1253-1261.
11. Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010; 170: 1892-1899.
12. Panossian Z, Drury PL, Cundy T. Reversible severe deterioration of glycaemic control after withdrawal of metformin treatment. Diabetologia 2012; 55: 267-269.
13. Wulffele MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002; 25: 2133-2140.
14. Strowig SM, Aviles-Santa ML, Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 2002; 25: 1691-1698.
15. Tong PC, Chow CC, Jorgensen LN, Cockram CS. The contribution of metformin to glycaemic control in patients with Type 2 diabetes mellitus receiving combination therapy with insulin. Diabetes Res Clin Pract 2002; 57: 93-98.
16. Perkovic V, Heerspink HL, Chalmers J, Woodward M, Jun M, Li Q, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013; 83: 517-523.
17. Fulop M, Hoberman HD. Phenformin-associated metabolic acidosis. Diabetes 1976; 25: 292-296.
18. Sogame Y, Kitamura A, Yabuki M, Komuro S. A comparison of uptake of metformin and phenformin mediated by hOCT1 in human hepatocytes. Biopharm Drug Dispos 2009; 30: 476-484.
19. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2003; 2: CD002967.
20. Holstein A, Nahrwold D, Hinze S, Egberts EH. Contra-indications to metformin therapy are largely disregarded. Diabet Med 1999; 16: 692-696.
21. Awadhi SSA, Clifford R, Sunderland V, Hackett L, Farah H, Shareef T. Do contraindications to metformin therapy deprive type 2 diabetic patients of its benefits? Int J Diabetes Metab 2008; 16: 81-84.
22. Brown JB, Pedula K, Barzilay J, Herson MK, Latare P. Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998; 21: 1659-1663.
23. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998; 338: 265-266.
24. Chan NN, Brain HP, Feher MD. Metformin-associated lactic acidosis: a rare or very rare clinical entity? Diabet Med 1999; 16: 273-281.
25. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 2008; 31: 2086-2091.
26. Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med 2004; 255: 179-187.
27. Lalau JD, Race JM. Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf 1999; 20: 377-384.
28. Runge S, Mayerle J, Warnke C, Robinson D, Roser M, Felix SB et al. Metformin-associated lactic acidosis in patients with renal impairment solely due to drug accumulation? Diabetes Obes Metab 2008; 10: 91-93.
29. Dell'Aglio DM, Perino LJ, Kazzi Z, Abramson J, Schwartz MD, Morgan BW. Acute metformin overdose: examining serum pH, lactate level, and metformin concentrations in survivors versus nonsurvivors: a systematic review of the literature. Ann Emerg Med 2009; 54: 818-823.
30. Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979; 16: 195-202.
31. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981; 12: 235-246.
32. Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol 1995; 35: 1094-1102.
33. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 2005; 20: 379-386.
34. Nies AT, Hofmann U, Resch C, Schaeffeler E, Rius M, Schwab M. Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS One 2011; 6: e22163.
35. Duong JK, Kumar SS, Kirkpatrick CM, Greenup LC, Arora M, Lee TC et al. Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. Clin Pharmacokinet 2013; 52: 373-384.
36. Duong JK, Roberts DM, Furlong TJ, Kumar SS, Greenfield JR, Kirkpatrick CM et al. Metformin therapy in patients with chronic kidney disease. Diabetes Obes Metab 2012; 14: 963-965.
37. Al-Hwiesh AK, Abdul-Rahman IS, El-Deen MA, Larbi E, Divino-Filho J, Al-Muhanna FA et al. Metformin in peritoneal dialysis: a pilot experience. Perit Dial Int 2014; 34: 368-375.
38. Lalau JD, Lacroix C, Compagnon P, de Cagny B, Rigaud JP, Bleichner G et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 1995; 18: 779-784.
39. Connolly V, Kesson CM. Metformin treatment in NIDDM patients with mild renal impairment. Postgrad Med J 1996; 72: 352-354.
40. Davis TM, Jackson D, Davis WA, Bruce DG, Chubb P. The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study. Br J Clin Pharmacol 2001; 52: 137-144.
41. McCartney MM, Gilbert FJ, Murchison LE, Pearson D, McHardy K, Murray AD. Metformin and contrast media-a dangerous combination? Clin Radiol 1999; 54: 29-33.
42. Royal College of Radiologists. Standards for Intravascular Contrast Agent Administration to Adult Patients, 2nd ed. London: The Royal College of Radiologists, 2010.
43. Endre ZH, Pickering JW. Biomarkers and creatinine in AKI: the trough of disillusionment or the slope of enlightenment? Kidney Int 2013; 84: 644-647.